The Neurosurgery Signal — Signal, Not Noise

Rapid review note

Journal Club is a rapid, AI-assisted appraisal layer. It highlights study design, effect estimates, and practice relevance, but it is still a briefing, not a replacement for the paper.

For education only. Not medical advice.

Paper snapshot

Rapid study overview

Open paper

DOI

10.1016/S0140-6736(05)66954-1

PMID

N/A

PICO

Population

Patients with metastatic epidural spinal cord compression (MESCC) from non-CNS, non-spinal column cancers, single compressive lesion, not paraplegic >48h, medically operable, expected survival ≥3 months

Intervention

Direct decompressive surgery followed by radiotherapy (30 Gy in 10 fractions)

Comparator

Radiotherapy alone (same dose)

Outcomes

Primary: ability to walk after treatment; Secondary: urinary continence, muscle strength (ASIA score), functional status (Frankel score), corticosteroid/opioid use, survival

Design

Type

Randomized controlled trial

Randomized

Yes

Multicenter

Yes

Blinded

N/A

Follow-up

Until death or last follow-up, median ~100 days

Primary endpoint

Ability to walk after treatment (ambulatory rate)

Secondary endpoints

Urinary continence maintenance
Muscle strength (ASIA score)
Functional status (Frankel score)
Corticosteroid use
Opioid analgesic use
Survival time

Practice impact

What this means

In patients with single-level metastatic epidural cord compression from solid tumors who are surgical candidates, direct decompressive surgery followed by radiotherapy provides significantly better ambulatory outcomes than radiotherapy alone, with 27% more patients walking and maintaining ambulation 4 months longer, without increased short-term mortality.

Bottom line

Direct decompressive surgery plus radiotherapy significantly improves ambulatory outcomes compared to radiotherapy alone in operable MESCC patients

Strength of evidence

low

Recommendation

change practice

Why it matters

27% absolute increase in ambulatory rate with surgery
Surgery patients walk 104 days longer median duration
No excess 30-day mortality/morbidity with surgery

What would change my mind

A validated full-text appraisal with explicit effect estimates and page-linked citations.

Critical appraisal

How strong is the paper?

Methods critique

Risk of bias

Randomization supports internal validity, but the trial was unblinded, stopped early at interim analysis, and enrolled a narrowly selected operable MESCC population, all of which can exaggerate apparent benefit.

Confounding

Stratified randomization by institution, tumor type, ambulatory status, spinal stability; multivariate analysis adjusted for covariates

Missing data

Intention-to-treat analysis used; 5 protocol violations (4 surgery, 1 radiation) included in analysis

Multiplicity

Interim analysis with O'Brien-Fleming stopping rule; multiple secondary endpoints analyzed without apparent adjustment

Notes

Non-blinded design introduces performance/detection bias
Surgical technique not standardized (tailored approach)
Central review of MRI and radiotherapy plans for protocol compliance

Stats check

NNT

NNT = 4 to achieve one additional ambulatory patient

Effect sizes

OR 6.2 (95% CI 2.0-19.8) for ambulatory ability
HR 0.47 (95% CI 0.25-0.87) for continence maintenance
HR 0.60 (95% CI 0.38-0.96) for survival

Absolute effects

27% absolute increase in ambulatory rate (84% vs 57%)
43% absolute increase in ambulatory recovery in non-ambulatory patients (62% vs 19%)
104 day median difference in ambulatory duration (122 vs 13 days)

Concerns

Wide confidence intervals for OR (2.0-19.8) reflect limited precision
Early stopping at interim analysis may overestimate effect
Multiple secondary endpoints without multiplicity adjustment

External validity

Who it applies to

Patients similar to the study population once inclusion criteria are verified.

Who it does not

Patients outside the verified eligibility criteria.

Generalizability notes

External validity depends on operative workflow, center expertise, and patient selection.

Evidence trace

Source trace and metadata

Citations (5)

claim_id

methods_critique.risk_of_bias

locator

p. 2 Methods

quote

Patients with certain radiosensitive tumours (lymphomas, leukaemia, multiple myeloma, and germ-cell tumours) were excluded

claim_id

methods_critique.risk_of_bias

locator

p. 3 Results

quote

odds ratio 6·2 (95% CI 2·0–19·8) p=0·001

claim_id

methods_critique.risk_of_bias

locator

p. 4 Results

quote

median 122 days vs 13 days, p=0·003

claim_id

stats_check.concerns

locator

p. 1

claim_id

practice_impact.bottom_line

locator

p. 1

Metadata

Generated at

2026-03-09T22:33:59.073Z

Version

pdf-archive-ingest-v1